A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
Pancreatic Cancer
DRUG: Gemcitabine|DRUG: LY293111|DRUG: placebo
6-month survival
Toxicity|tumor response|PK
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.